Hexaxim is a 6-in-1 vaccine to protect infants and toddlers against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.  It is a preservative free liquid formulation containing  Diphtheria and  tetanus toxoids, pertussis (acellular component), Recombinant Hepatitis B surface antigen, Inactivated Poliomyelitis virus and Haemophilus influenzae type b polysaccharide conjugated to tetanus protein. ( DTPa-hepB-IPV-Hib)

Immunization Guideline:

0.5 ml of ready liquid vaccine should be injected via intramuscular mode. The recommended injection sites are generally the antero -lateral aspect of the upper thigh in infants and toddlers and the deltoid muscle in older children. Hexaxim can be given to infants starting from minimum age 6 weeks.

Three primary doses at 6wk, 10wk and 14 wk followed by a booster dose in 2nd year of life. If Hep B dose is not given at birth, a  Hep B vaccine booster dose (or Hexaxim) must be given at 6 months after the last primary dose. If Hep B dose is given at birth, after a 3-dose primary vaccination, Hexaxim or a pentavalent DTaP-IPV/Hib vaccine can be administered for the booster. Hexaxim can be used as the booster dose even after previous vaccination history with another hexavalent vaccine or pentavalent DTaP-IPV/Hib vaccine.


History of severe allergic reaction to any component of the vaccine or to any pertussis vaccine, after previous administration of the vaccine or a vaccine containing the same components or constituents. Encephalopathy of unknown etiology within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (whole cell or acellular pertussis vaccines). In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria, tetanus, hepatitis B, poliomyelitis and Hib vaccines. Children suffering from progressive neurological disorder, uncontrolled epilepsy and progressive encephalopathy. Vaccination must be postponed in cases of moderate or severe febrile and/or acute disease.  Low-grade fever does not constitute a contraindication.

Additional information


Sanofi Pasteur




6 weeks


1 Dose


Ready to Use






Diphtheria-Tetanus-Pertussis (acellular), Haemophilus influenzae type b, Polio vaccine – injectable, Hepatitis B